Latest news with #ARPA-H
Business Wire
30-04-2025
- Health
- Business Wire
Statement from Ilana Golant, Founder and CEO of the Food Allergy Fund
NEW YORK--(BUSINESS WIRE)--Today at the Food Allergy Fund Summit in New York City, Wade Shen, Director of Proactive Health at the Advanced Research Projects Agency for Health (ARPA-H), shared the agency's strategic priorities for advancing research and innovation to prevent, mitigate, and delay diseases, including food allergies and other urgent health challenges. He encouraged the event's attendees and the larger research community to engage with the agency as it helps to accelerate work on food allergies. 'On behalf of the Food Allergy Fund and our entire community, I extend my heartfelt thanks to Wade Shen and Dr. Jason Roos for affirming the agency's commitment to making allergic diseases a national health priority. Your leadership in driving research into the root causes of food allergies is essential to our mission: to prevent, treat, and ultimately cure this chronic disease. ARPA-H's bold, future-focused approach to funding transformative science reflects the growing recognition of food allergies as a serious and escalating public health issue. 'Food allergies are the canary in the coal mine for chronic disease and addressing them can unlock critical insights that can transform the future of public health. We are grateful for your partnership and dedication to advancing meaningful change for the millions of Americans affected by food allergies.' About the Food Allergy Fund The Food Allergy Fund (FAF) is the leading nonprofit dedicated to funding cutting-edge research to prevent, diagnose, and treat food allergies, a growing public health crisis affecting 10 percent of people in the United States and more than 300 million globally. Through innovative research grants and thought leadership summits, FAF is an incubator and convener, uniting scientists, policymakers, industry leaders, and entrepreneurs to drive breakthroughs. FAF's mission is to create a future where no one has to suffer from food allergies. To learn more, visit
Yahoo
10-04-2025
- Business
- Yahoo
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain
Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, April 10, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences, US Pharmacopeia (USP), On Demand Pharmaceuticals, and Isolere Bio by Donaldson. This two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems. Under the $29 million contract, Ginkgo will combine its Enzyme Services and expertise in cell-free systems with the expertise and experience of its partners in upstream extract preparation, API downstream processing, quality metrics, and modular, on-demand API manufacturing methods, with the aim of developing affordable cell-free biological processes to produce essential medicines. By utilizing wheat germ - an abundant and renewable resource - and developing methods to produce medicines exactly where and when they are needed, the partnership seeks to create a new paradigm for domestic manufacturing of critical medicines, stabilizing and reshoring supply chains for essential pharmaceuticals. This strategy shifts API production from fragile global supply chains to a robust, decentralized system using Cell-Free Protein Synthesis (CFPS). Bringing the Kernel of Innovation from Farm to Pharma The project brings together non-profit and corporate partners based in Massachusetts, Kansas, Maryland, and Minnesota, combining expertise to develop scalable, distributed manufacturing solutions to strengthen supply chain resilience for active pharmaceutical ingredients. Ginkgo Bioworks will apply its cell programming platform, utilizing machine learning, computational tools, and predictive approaches to engineer enzymes and optimize cell-free expression systems. "We are thrilled for the opportunity to work on this exciting project with ARPA-H and our teammates to allow Americans to reap the benefits when we bring together innovations in farm and pharma," said Jesse Dill, Senior Director of Business Development at Ginkgo Bioworks. "From small molecule compounds to biologics, we believe this project can sow the seeds of medical innovation, growing a new manufacturing paradigm for essential medicines using affordable cell-free biological processes, to reshore and stabilize these critical, life-saving supply chains." WHEAT aims to demonstrate scalable and decentralized processes for CFPS-based production of complex APIs, focusing on targets where biocatalysis can wholly or partially complete syntheses, and where current supply chains are constrained to natural products or overseas providers. Additionally, WHEAT's innovations in protein post-translational modifications (PTMs) aim to establish a foundation suitable for production of biologics such as growth factors and insulin, offering a broader range of applications and establishing a foundation for further expanding the potential of CFPS to even more complex products. An Integrated Platform Addressing Cost, Distribution, and Quality Needs "At Tritica Biosciences, we are excited to collaborate with Ginkgo Bioworks and our partners to revolutionize pharmaceutical manufacturing," said Chris Miller, Founder and CSO of Tritica Biosciences. "By harnessing the power of wheat germ cell-free systems, we're planting the future of medicine, helping to make production more efficient, flexible, and localized." "Economic and supply chain security for essential medicines is critical," said Eugene Choi, President and COO of On Demand Pharmaceuticals. "This collaboration brings together innovative technologies and expertise to transform how we produce and access these vital drugs." "Advanced manufacturing technologies and biomanufacturing are critical to bolstering supply chain resilience," said Ronald T. Piervincenzi, Ph.D., CEO of USP. "USP is proud to contribute our scientific expertise to develop standardized solutions, process control strategies, and quality testing methods that pave the way for broader adoption, future regulatory approval and commercialization." "Isolere Bio by Donaldson is eager to collaborate with these great organizations on this transformative product," said Michael Dzuricky, Director of R&D at Isolere Bio by Donaldson. "The goals of this project align perfectly with our life science vision of building innovative bioprocessing solutions that can reduce costs and increase speed of development for essential reagents and medicines." Sowing the Future of Medicine This program represents one of the first initiatives within ARPA-H's Scalable Solutions Office, aimed at transforming the health of all Americans by improving the speed, scale, and access to medical treatments and enhancing health security in the US. By establishing a faster and cheaper way to develop essential medicines, the collaboration positions Ginkgo Bioworks as a leader in cell-free small molecule and biologics manufacturing, leveraging its engineering capabilities and experience at scale. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. GINKGO BIOWORKS INVESTOR CONTACT:investors@ GINKGO BIOWORKS MEDIA CONTACT:press@ About Tritica Bio At Tritica Biosciences, we are revolutionizing synthetic biology through a groundbreaking technology designed for rapid discovery, prototyping, and manufacturing, with applications from farm to pharma. Our focus is innovation, and we are committed to accelerating the bio-manufacturing process and delivering new products that address global challenges in biotechnology. Our proprietary strain-free discovery platform, seamlessly integrated with scaled production, enables us to iterate, optimize, and launch products at unprecedented speeds. Founded in 2017, Tritica Biosciences is driven by a team of experts dedicated to pushing the boundaries of biotechnology. For more information visit or find us at LinkedIn. About US Pharmacopeia USP is an independent scientific organization that collaborates with the world's top experts in health and science to develop quality resources and standards for medicines, dietary supplements, and food ingredients. Through our resources, standards, advocacy and education, USP helps increase the availability of quality medicines, supplements and foods for billions of people worldwide. For more information, visit: About On Demand Pharmaceuticals On Demand Pharmaceuticals is a new kind of pharmaceutical company. We are focused on providing healthcare professionals and their communities access to the most agile medicine-making capabilities, including subscription services ("Medications as a Service") and point of care delivery systems ("Pharmacy on Demand") that integrate production oversight innovations with our robust formulary. Our enabling capabilities in drug substance and drug product are vertically integrated to produce a robust and resilient supply chain that meets our customers' needs. About Isolere Bio by Donaldson Isolere Bio by Donaldson is an innovator in biopharmaceutical purification technologies, specializing in streamlined solutions for complex biologics. The company works diligently to enhance the efficiency, purity and cost-effectiveness of biopharmaceutical processes by leveraging cutting-edge materials into next generation solutions. Each product is designed with scalability and sustainability in mind to enable customers to rapidly and reliably commercialize life-saving therapies. For more information, visit Incorporated in 2017, Isolere Bio became part of Donaldson Company (NYSE: DCI) in early 2023. For more information, visit Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. View original content to download multimedia: SOURCE Ginkgo Bioworks
CNN
24-03-2025
- Health
- CNN
White House to nominate Dr. Susan Monarez to lead CDC
The White House will nominate Dr. Susan Monarez, the current acting director of the US Centers for Disease Control and Prevention, to lead the agency, President Donald Trump said Monday. The move comes weeks after the White House abruptly withdrew its nomination of Dr. Dave Weldon to lead the public health agency. Monarez is a veteran of government service who was previously the deputy director of ARPA-H, the Advanced Research Projects Agency for Health, an agency tasked with doing innovative, high-stakes research. 'Dr. Monarez brings decades of experience championing Innovation, Transparency, and strong Public Health Systems. She has a Ph.D. from the University of Wisconsin, and PostDoctoral training in Microbiology and Immunology at Stanford University School of Medicine,' Trump posted on Truth Social. Claiming that Americans have 'lost confidence in the CDC due to political bias and disastrous mismanagement,' he added, 'Dr. Monarez will work closely with our GREAT Secretary of Health and Human Services, Robert Kennedy Jr. Together, they will prioritize Accountability, High Standards, and Disease Prevention.' In the past, the CDC director has been appointed to lead the office, but the nominee will require approval by the Senate starting this year. Earlier this month, the White House withdrew its nomination of Weldon after White House officials privately voiced concerns about his comments expressing skepticism about vaccines. Even Kennedy, who has a long history of questioning vaccines, had concerns, the sources said. CNN's Alayna Treene, Kit Maher and Brenda Goodman contributed to this report.
